[Form 3] West Pharmaceutical Services, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Robert W. McMahon, the company's SVP & Chief Financial Officer, reported an initial beneficial ownership position in West Pharmaceutical Services (WST). He directly holds restricted stock units of 3,168 and 12,670 shares, and two stock options covering 7,647 and 7,137 shares with an exercise price of $240.33. The options become exercisable on 08/11/2026 and expire on 08/11/2035. In total the reported awards underlie 30,622 common shares and are reported as direct beneficial ownership.

Insights

Securities Analyst

TL;DR: Routine Section 16 disclosure showing executive equity awards totaling 30,622 underlying shares; no unusual terms.

The filing documents typical equity compensation for a senior executive: two restricted stock unit grants and two stock options. The options carry an exercise price of $240.33 and long-dated expirations to 2035, with exercisability beginning in 2026. This is a standard reporting of direct holdings under Section 16 and, on its face, does not signal material corporate or market-moving events.

Corporate Governance Expert

TL;DR: Standard governance disclosure that records direct equity-linked incentives for a senior officer; procedural and non-material.

The Form 3 records direct ownership of RSUs and options by the SVP & CFO, consistent with routine executive compensation practices and required insider reporting. Vesting schedules and exercisability are disclosed for transparency. The disclosure itself is governance-compliant and does not indicate departures, transfers, or unusual governance actions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McMahon Robert W.

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2025

3. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	(1)	Common Stock	3,168	$0	D
Rst. Stock Unit	(2)	(2)	Common Stock	12,670	$0	D
Stock Option (Right to Buy)	08/11/2026(1)	08/11/2035	Common Stock	7,647	$240.33	D
Stock Option (Right to Buy)	08/11/2026(1)	08/11/2035	Common Stock	7,137	$240.33	D

Explanation of Responses:

1. This award vests in four equal installments beginning on August 11, 2026.

2. This award vests in three installments. 4,223 shares will vest six months from the grant date, 6,335 shares will vest 12 months from the grant date, and 2,112 shares will vest 24 months from the grant date.

	/s/ Caitlin Hippeli, as an agent for Robert W. McMahon	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Robert W. McMahon disclose on the Form 3 for WST?

He reported direct beneficial ownership of restricted stock units of 3,168 and 12,670 shares and two stock options for 7,647 and 7,137 shares.

How many total shares underlie McMahon's reported awards?

30,622 total common shares underlie the reported RSUs and stock options.

What is the exercise price and term of the reported stock options?

The options have an exercise price of $240.33; they become exercisable on 08/11/2026 and expire on 08/11/2035.

Are the reported holdings direct or indirect?

All listed awards are reported as Direct (D) beneficial ownership.

What is McMahon's role at West Pharmaceutical (WST)?

He is reported as the company's SVP & Chief Financial Officer.